FY2025 EPS Estimates for Elutia Raised by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share (EPS) estimate for Elutia to ($0.52), improving from a prior estimate of ($0.65).
• Elutia recently reported ($0.26) EPS for the last quarter, which fell short of analyst expectations of ($0.17).
• Institutional investors hold 74.03% of Elutia's stock, reflecting significant institutional interest in the company.

Elutia Inc. (NASDAQ:ELUT - Free Report) - Stock analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of Elutia in a research note issued to investors on Tuesday, August 19th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings per share of ($0.52) for the year, up from their previous estimate of ($0.65). The consensus estimate for Elutia's current full-year earnings is ($1.74) per share.

Elutia (NASDAQ:ELUT - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). The company had revenue of $6.26 million during the quarter, compared to analyst estimates of $6.55 million.

Separately, Lake Street Capital decreased their target price on Elutia from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Elutia presently has a consensus rating of "Buy" and an average target price of $8.00.

Elutia Stock Up 5.0%

Shares of Elutia stock opened at $2.12 on Thursday. The stock has a market cap of $87.17 million, a PE ratio of -2.00 and a beta of 0.88. The business has a fifty day simple moving average of $2.01 and a 200-day simple moving average of $2.29. Elutia has a 12 month low of $1.61 and a 12 month high of $5.12.

Institutional Trading of Elutia

A number of institutional investors and hedge funds have recently made changes to their positions in ELUT. OMERS ADMINISTRATION Corp acquired a new stake in shares of Elutia in the first quarter worth about $28,000. XTX Topco Ltd bought a new position in shares of Elutia in the second quarter worth about $28,000. Jane Street Group LLC bought a new position in shares of Elutia in the first quarter worth about $48,000. Arcus Capital Partners LLC bought a new position in shares of Elutia in the first quarter worth about $51,000. Finally, Northern Trust Corp increased its stake in shares of Elutia by 30.0% in the fourth quarter. Northern Trust Corp now owns 17,957 shares of the company's stock worth $67,000 after purchasing an additional 4,148 shares during the period. Institutional investors and hedge funds own 74.03% of the company's stock.

Elutia Company Profile

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.